Equity Overview
Price & Market Data
Price: $0.32
Daily Change: +$0.012 / 3.75%
Range: $0.29 - $0.32
Market Cap: $18,492,512
Volume: 548,414
Performance Metrics
1 Week: 1.02%
1 Month: -10.55%
3 Months: -33.33%
6 Months: -31.19%
1 Year: -85.59%
YTD: -57.46%
Company Details
Employees: 28
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.